200619-13-2

200619-13-2 structure

Name: DRF-1042
Chemical Name: drf-1042
CAS Number: 200619-13-2
Molecular Formula: C₂₂H₂₀N₂O₆
Molecular Weight: 408.404
Catalog: Signaling Pathways Cell Cycle/DNA Damage Topoisomerase
Create Date: 2017-07-29 02:17:37
Modify Date: 2024-01-10 17:46:44
DRF-1042 is an orally active camptothecin analog, which acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines[1][2].

Name	drf-1042
Synonyms	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-12-(2-hydroxyethoxy)-, (4S,12S)- (4S,12S)-4-Ethyl-4-hydroxy-12-(2-hydroxyethoxy)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 5-(2'-Hydroxyethoxy)-20(S)-camptothecin 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione,4-ethyl-4-hydroxy-12-(2-hydroxyethoxy)-,(4S) UNII-461WVF206P

Description	DRF-1042 is an orally active camptothecin analog, which acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase
References	[1]. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. [2]. Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.